Asterias Biotherapeutics (AST) Reports In-Line Q3 EPS, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AST Hot Sheet
Join SI Premium – FREE
Asterias Biotherapeutics (NYSE: AST) reported Q3 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $1.69 million versus the consensus estimate of $1.48 million.
For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Host Hotels & Resorts (HST) Tops Q3 EPS by 1c; offers guidance
- Mueller Water Products, Inc. (MWA) Reports In-Line Q4 EPS; Offers Guidance
- Atmos Energy (ATO) Tops Q4 EPS by 3c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
